منابع مشابه
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...
متن کاملdabigatran etexilate - a novel oral anticoagulant for bleeding complications
thromboembolic disease is a common cause of morbidity and mortality. thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. dabi...
متن کاملIs the bleeding time prolonged in oral anticoagulant treatment?
; In a recent issue of Thrombosis and Haemostasis, Dr. Maron1 giu et al. (1) made some comments on a study of ours on bleeding time techniques (2). We thank Dr. Marongiu and co-authors for their interest, and we like to answer their remarks. 1 To summarise our study: we compared three bleeding time J techniques: Ivy, Simplate II parallel to the antecubital crease '("horizontal" i.e. perpendicul...
متن کاملBleeding during oral anticoagulant therapy: warning against a greater hazard.
BACKGROUND Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of ...
متن کاملHow I treat target-specific oral anticoagulant-associated bleeding.
Target-specific oral anticoagulants (TSOACs) that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin K antagonists (VKAs) and low-molecular-weight heparin (LMWH). Although these agents have practical advantages compared with VKAs and LMWH, there are no antidotes that reverse their anticoagulant effect. Clinical evidence for...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Brazilian Dental Science
سال: 2017
ISSN: 2178-6011
DOI: 10.14295/bds.2017.v20i3.1379